PMAC 2017 ACCESS TO MEDICINES: HOW TO FIX THE BROKEN SYSTEM

Changing R&D model

DNDi Drugs for Neglected Diseases initiative

mlallemant@dndi.org

2016 MSF report: "The way it is conducted today, Research and Development (R&D)..."

- Do not deliver for diseases that are not sufficiently lucrative
 - No investment in drugs, diagnostics and vaccines for people who cannot afford them
- Do not prioritize according to public health needs
 - E.g. antibiotics, anti-tuberculosis
- Do not deliver affordable products
 - Exclusive patent rights preventing competition (eg. Cancer drugs, DAAs)
- Does not use scientific and financial resources efficiently and effectively
 - Isolation, competition, secrecy, redundancy

MSF Access Campaign: Lives on the edge: time to align medical research and development with people's health needs 2016

Changing R&D model



http://www.oecd.org/health/

managing-new-technologies-in-health-care (Jan 2017)






driver of growth in health spending



do not always create high benefits



DNDi





fully from technology

Political leadership at the center of solutions

- Government must demand transparency
- Governments must change incentive mechanisms to steer and finance biomedical innovation
 - Use all the legal tools at their disposal to ensure access and resist demands for additional exclusivity rights
 - Reclaim more than the product itself for their investment
 - incentives and publicly funded basic/translational research
 - Embrace new approaches that de-link R&D costs and product price (eg. product development partnerships)
- Acting on behalf of patients, governments must set priorities and coordinate efforts

MSF Access Campaign: Lives on the edge: time to align medical research and development with people's health needs 2016



Changing R&D model

Origins of DNDi

1999

- First meeting to describe the lack of R&D for neglected diseases
- MSF commits the Nobel Peace Prize money to the DND Working Group
- JAMA article: 'Access to essential drugs in poor countries -A Lost Battle?'


July 2003

- Creation of DNDi
- Founding partners:
 - Institut Pasteur, France
 - Indian Council of Medical Research, India
 - Kenya Medical Research Institute, Kenya
 - Médecins Sans Frontières
 - Ministry of Health, Malaysia
 - Oswaldo Cruz Foundation/Fiocruz, Brazil
 - WHO –TDR (Special Programme for Research and Training in Tropical Diseases) as a permanent observer






DNDi approach: Address immediate patient needs & deliver innovative medicines - Short- and long-term



DND*i*'s virtual R&D organization: Success only possible through innovative partnerships



PDPs

Pharmaceutical

Universities

& Research Institutes

Int. Org.

& NGOs

CROs



7 new treatments delivered, recommended, implemented







DNDi











- Easy to use
- 🖌 Affordable
- 🗸 Field-adapted
- Non-patented

- 30 projects, 8 diseases areas
- 13 entirely new chemical entities (NCEs)
- Over 160 partnerships, most in endemic countries
- **160 staff**, half in endemic countries & 700 people working on DNDi projects
- EUR 400 million raised equally from public and private sources
- 4 regional disease-specific clinical trial platforms/ networks and several technology transfers


Diversification of donors: EUR 400M secured out of EUR 650M to deliver 16-18 treatments by 2023

- 50% public 50% private
- max. 25% per donor

=> Delinkage between R&D funding and final product pricing



How do we do it... operationally






For each disease, a Target Product Profile is developed to guide decisions (e.g. paediatric HIV)

IDEAL CHARACTERISTICS (TPP)

- 4 ARVs in one
- Simple to open and use with water, milk, food
- Good taste
- No fridge needed
- Suitable for infants (<2 months - 3 years)
- TB-treatment compatible
- Affordable for governments




PROCESS

DNDi Drugs for Neglected Diseases initiativ

Paediatric HIV: Scaling up with the right tools, right now and bringing '4-in-1's formulations for children







Today

LPV/r

Only available treatment for young children: unpalatable (42% alcohol), requires refrigeration, expensive, difficult to store and transport

2016 'Super-boosting' ritonavir is recommended by WHO in ARV guidelines 2016 for TB/HIV co-infected children

By 2018 To deliver:

2 new **'4-in-1's** childappropriate formulations that are safe, easy to administer, welltolerated & heat-stable




Sleeping sickness: Two new treatments in development to support sustainable elimination



DNDi Drugs for Neglected Diseases


NECT = Nifurtimox-Eflornithine

Dynamic portfolio: New disease areas, new models...





Abundant R&D pipeline... but many drug candidates abandoned





A pan-genotypic treatment for less than \$300

- DND*i*, Pharco and Presidio agreement to test combination of sofosbuvir + ravidasvir
- Partnership with Malaysia and Thailand to conduct Phase II/III multicentre study (900 patients)
- Using innovative licensing agreement or TRIPS flexibilities




theguardian

April 13, 2016

Hepatitis C treatment for under \$300 coming soon

Drugs for Neglected Diseases initiative says drug successfully tested in Egypt could be available within 18-24 months



By 2023: Deliver 16 to 18 treatments with EUR 650 million

2016

7 treatments delivered

2023 16-18 treatments

2023 9 -11 additional

treatments delivered

Influence the R&D landscape for neglected patients

Ğ

- Political leadership for needs-driven R&D
- Creation of a global fund and mechanism
- Evidence on alternative R&D models

DNDi

Develop treatments for people suffering from neglected diseases

- Deliver 16-18
 treatments
- 3 new chemical entities (NCEs)
- ~10 disease areas
- Focus on access and measure impact

Strengthen research capacity, led by Regional Offices

- R&D platforms in diseaseendemic countries
- Regionally-driven
 initiatives
- Patient access to treatments
- Transfer of technology

Thank you very much for your attention




• Backup slides



The NTD Drug Discovery Booster

- Objective: speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease
- Booster launched in 2015
- 3 Japanese pharma companies on board since the start
- Innovation: multilateral and crosscompany comparative approach + iterative search
- Already 6 seed compounds submitted to the booster and > 1,600 analogues tested






Innovation & Access on the political agenda: Influencing the R&D landscape for neglected patients

DND



13 years of discussions at WHA, with 6 resolutions (2003-2016) 2008 2016 2013 Demo Priority setting role 2003 2006 Expert 2010 projects, Obs., voluntary pooled Working CFWG CIPIH IGWG Global R&D fund, core principles, Group on Obs. delinkage R&D Connect **R&D Blueprint for Emerging Pathogens** the dots July 2016: UN High-Level Panel on Access to Medicines September 2016: UN High-Level Meeting on AMR

Over 10-Year Discussion at World Health Assembly Level to Find a Sustainable Solution



Need to develop an overarching framework: priority-setting, sustainable funding, and principles

